CartiHeal wins FDA breakthrough designation for Agili-C implant

CartiHeal announced that it received FDA breakthrough device designation for its Agili-C implant for treating cartilage lesions.

Kfar Saba, Israel.-based CartiHeal’s Agili-C implant is a proprietary implant for treating cartilage lesions in arthritic and non-arthritic joints, according to a news release.

The implant is currently being observed in a pivotal investigational device exemption study comparing it to the current surgical standard of care that is microfracture and debridement.

Get the full story on our sister site, MassDevice.

Original Article: (http://feedproxy.google.com/~r/MedicalDesignAndOutsourcing/~3/BOalNcXbEkQ/)